| Trial name or title | CATNON trial (EORTC study 26053‐22054) |
| Methods | Phase 3 randomised, open‐label study with 2x2 factorial design. Web‐based randomisation (1:1:1:1) |
| Participants | 784 randomised Patients were 18 years or older with newly diagnosed non‐co‐deleted anaplastic glioma with WHO performance scores of 0 to 2 |
| Interventions | RT RT + adjuvant TMZ RT + concurrent TMZ RT + concurrent TMZ + adjuvant TMZ |
| Outcomes | 5‐year PFS and OS, adverse events, HRQoL and cognitive effects |
| Starting date | Dec 2007 ‒ ongoing |
| Contact information | Martin van den Bent; m.vandenbent@erasmusmc.nl |
| Notes | Interim results were published in 2017, which showed that adjuvant TMZ was associated with significant 5‐year survival benefit in this population. (One might expect that cognitive data will therefore be biased by the greater attrition in the study arms with adjuvant TMZ). Neurocognitive data will be presented in 2020/21 (personal communication) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.